Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • $2.5M age discrimination award against AutoNation upheld
    • Law firm did not infringe by purchasing rival’s mark as Google Ads keyword
    • Peirce, Uyeda say SolarWinds customer admins are regulation by enforcement
    • Former students allege elite private universities conspired to raise cost of education through financial aid price-fixing scheme
    • Telemedicine prescriptions of controlled substances likely extended into 2025, special registration possible
    • Fisher-Price, Mattel face claims of failure to warn of risks related to infant swings
    • Apple, Goldman Sachs fined more than $89M for mishandling disputes, misleading consumers
    • Appellate court finds definition of ‘oncological protocol’ irrational
    • Dow Jones, New York Post sue Perplexity AI for ‘massive’ illegal copying and trademark harm from ‘hallucinations’
    • EC clears JD Sports acquisition of Courir, fines Czech, Austrian state railways $53 million
    • Former IDF member who alleged discrimination based on Israeli heritage can’t proceed anonymously
    • HHS granted summary judgment in Novartis’ challenge to Drug Price Negotiation Program
    • Kentucky bank, trade groups sue CFPB, Chopra over personal financial data rights rule
    • NHTSA reveals 2025 vehicle lineup for comprehensive safety testing
    • Whistleblowers challenge award denials in CFTC enforcement against ‘off-channel’ communications
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Corporate Counsel Daily, Telemedicine prescriptions of controlled substances likely extended into 2025, special registration possible, (Oct 23, 2024)

    By Cathleen Calhoun, J.D.

    The Drug Enforcement Administration (DEA) appears poised to again extend the COVID-19 telemedicine flexibilities for controlled substances in some way based on its draft proposed rule that is not yet publicly available.

    The most recent extension of th ...

    By Cathleen Calhoun, J.D.

    The Drug Enforcement Administration (DEA) appears poised to again extend the COVID-19 telemedicine flexibilities for controlled substances in some way based on its draft proposed rule that is not yet publicly available.

    The most recent extension of the COVID-19 telemedicine flexibilities for controlled substances ends soon—on December 31, 2024. Arguments for and against another extension of telemedicine flexibilities for prescriptions of controlled substances and requirements of current law are factors in the DEA’s determination of how telemedicine prescriptions for controlled substances will change or remain the same. The DEA may require some form of special registration in 2025 for telemedicine prescriptions of controlled substances. Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescriptions.

    To read the entire article, click here.

    MainStory: TopStory StrategicPerspectives CoverageNews AccessNews HealthReformNews AgencyNews DrugBiologicNews PartDNews PrescriptionDrugNews ProviderNews GCNNews BillingNews CoPNews MedicaidNews Covid19

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use